

REMARKS

As a result of the foregoing amendment, the specification has been corrected pursuant to the Examiner's instructions.

In addition, claims 10, 12 and 15 have been amended to recite the specific steps for raising the antibodies namely, injecting a laboratory animal and thereafter collecting the anitsera. This is in accordance with the original disclosure at page 14, in paragraph [46].


Accordingly, it is submitted that the objection to the claims with respect to the spelling of dichlorotyrosine as well as the rejection under the second paragraph 35 U.S.C. has been obviated in as much as the claims recite how the antigen is used to raised antibodies. Accordingly, the rejection under the second paragraph 35 U.S.C 112 should be withdrawn.

The Examiner's indication that the claims 6-9 are allowable and claims 10-12, and 14-15 would be allowable if rewritten to overcome the rejections under 35 U.S.C 112 is appreciatively acknowledged.

It is believed all of the requirements have now been accomadated and this application is in condition for allowance and favorable reconsideration and prompt Notice of Allowance are earnestly solicited.

Respectfully submitted,

Dated: December 28, 2007



Jules E. Goldberg - Reg. No. 24,408
Reed Smith LLP
599 Lexington Avenue
New York, NY 10022
Tel. No. (212) 521-5403

Attorneys for Applicants